Prominent Matters Walder Wyss's One-Firm Approach Ensures That Our
Total Page:16
File Type:pdf, Size:1020Kb
Prominent Matters Walder Wyss’s one-firm approach ensures that our fully integrated teams work seamlessly across all our six Swiss locations to handle the most complex cases. Around 240 legal experts make Walder Wyss one of the most successful Swiss commercial law firms. We provide services to national and interna- tional clients as the «Law Firm of Choice» in Switzerland. «Their client service and multijurisdictional Walder Wyss established a leading position in all releveant areas and is once again being top-ranked work is excellent.» and law firm with one of the broadest footprints in Switzerland by the «Bilanz / Le Temps» ranking Chambers Europe, 2020 2020 – the most important ranking by leading Swiss publications focusing on the legal market in Switzerland. «Their work was perfectly tailored to our We have handled a number of high-profile cases in a wide range of fields of expertise, such as (recent requirements: It was precise, fast and efficient.» assignments only): Client Feedback – Handling transactions with an aggregate deal – Representing banks, securities dealers and «Excellent lawyers who provide an outstanding value exceeding CHF 20bn during the last fund management companies in regulatory quality as well as great responsiveness.» 12 months. matters (including licensing or enforcement Legal 500, 2019 – Advising on many of the most significant proceedings as well as distribution matters). domestic and cross-border M&A and capital – Representing major multinationals in their markets transactions, public tender offers and successful trademark prosecution and «Counting on Walder Wyss as a very reliable roughly 50 private M&A transactions (with a litigation efforts. partner, we can focus fully on our business.» deal value exceeding CHF 5m each) during the – Currently representing clients in more than Client feedback last 12 months. 20 international arbitrations, in particular in – Several hybrid, convertible and regulatory construction, joint-ventures and post-M&A «They are very dedicated and committed bond / note issuances with an aggregate deal disputes. lawyers. They have a very open style of volume exceeding CHF 10bn. – Several complex merger control proceedings communication. They are very diligent, don’t – Frontrunner for Swiss structured finance (phase I and phase II) before the Swiss mind long hours and put in the extra hours if transactions and involved in most public and Competition Commission. they are needed.» private ABS transactions, synthetic transac- – Representing multinational pharmaceutical Client feedback tions, covered bond transactions and other companies in their reimbursement & pricing securitisations. strategies, applications and appeals before – Representing banks and other lenders and Federal Courts. borrowers in large scale domestic and inter- – Trusted advisor to the Swiss Government in national finance transactions, including acqui- large scale procurement matters. sition finance, corporate finance and asset – Dedicated start-up desk (www.startuplaw.ch) finance. advising founders or investors of more than – Several substantial real estate transactions 100 start-ups in all kind of investment cycles, (listed and unlisted). including numerous spin-offs from leading – Several IPOs, advising the issuer or the invest- Swiss Universities (ETH, HSG, and EPFL). ment banks. – Several landmark and «bet the company» – Complex domestic and cross-border corporate decisions from courts throughout the country, restructurings and insolvency proceedings. including the Swiss Federal Supreme Court. – Numerous venture capital and private equity transactions. Factsheet Finance, Capital Markets & Corporate, M&A comprising 40 North Latitude Master Fund Ltd. (40 North) and two Corvex funds as limited Recent experience includes advising: Regulatory partners, and 40 North on its acquisition of a Recent experience includes advising: – Nestlé on its CHF 10bn sale of its Skin Health significant stake in SIX-listed Clariant AG, of Business. – Goldman Sachs, on the establishment of a new which 24.99% were sold to Saudi Basic Indus- – The private sellers on the sale of NVT to Blue Swiss residential mortgage business platform. tries Corporation. Sail Medical Co., Ltd. (a leading Chinese medi- – CRISPR Therapeutics on its CHF 200m ATM – Bank J. Safra Sarasin on the acquisition from cal device company, listed at Shenzhen Stock Programme. Bank Hapoalim of a majority of the portfolio Exchange). – The underwriting banks on the IPO of Medartis of international private banking customers in – Engie on its investment in tiko Energy Solu- Holding AG at the SIX Swiss Exchange. Switzerland, Luxembourg and Israel. tions Ltd, a pioneer in the development of intel- – Aluflexpack in its IPO on the SIX Swiss – The J. Safra and P. Peress groups in their ligent energy management systems for the Exchange. acquisition of Regus and Spaces workspaces residential market. – Valiant Bank (SIX-listed) on its inaugural franchises in Switzerland from IWG for a con- – SIX-listed Bellevue Group on the sale of Bank CHF 250m Swiss covered bond. sideration of CHF 120m. am Bellevue to KBL European Private Bankers. – Essentially all originators and issuers in rela- – Recordati on the acquisition of the worldwide tion to Swiss public ABS transactions, inclu- rights for Signifor and Osilodrostat for the ding AMAG Leasing, Multilease (Emil Frey), Litigation & Arbitration treatment of the Cushing’s disease and the Cembra and Swisscard as well as originators Recent experience includes advising and repre- Cushing’s syndrom from Novartis. and issuers of private ABS transactions. senting: – Boehringer Ingelheim on the EUR 325m – Glarner Kantonalbank on its CHF 100m per- – An Indian conglomerate in a USD 1.2bn com- acquisition of Amal Therapeutics SA, a private petual subordinated Additional Tier 1 bond. mercial dispute. Swiss biotechnology company focused on can- – A syndicate of lenders in connection with the – Advising an international financial service cer immunotherapy. public takeover offer for all shares in Kuoni provider in multi-billion litigation proceedings – NovImmune SA, a private Swiss biotechno- Reisen Holding AG (SIX-delisted). in various jurisdictions. logy company, on its CHF 510m sale of the – Finance providers in connection with the pub- – A Russian party in a USD 200m LCIA arbitra- immunology business unit to Swedish Orphan lic takeover offer for all shares in Immomen- tion. Biovitrum AB (STO:SOBI). tum AG (BX-delisted). – A chemical multinational in a USD 330m – Aduno Holding AG on the CHF 277m sale of – Cembra on its refinancing transaction of dispute. 100% of the shares in cashgate AG to SIX- SME loans sourced through Lendico’s (Post – A French-listed multinational in a complex listed Cembra Money Bank AG. Finance’s) marketplace lending platform. multi-jurisdiction large scale fraud matter in – The Independent Bid Committee of the board – Swiss Life Ltd. (SIX-listed) on its EUR 750m excess of EUR 250m in white-collar crime and of directors of Nasdaq Stockholm listed perpetual subordinated bond and its civil proceedings involving Switzerland. Oriflame Holding AG with regard to all Swiss CHF 600m inaugural green bond. – A UHNWI in a USD 120m dispute over a real legal aspects of the public tender offer of – Gategroup (SIX-delisted) on its CHF 350m estate project. Walnut Bidco Plc to the shareholders of bond. – A European bank against a former manager Oriflame Holding AG. – Baloise Group (SIX-listed) on its inaugural charged with embezzling more than EUR – Canopius, a global speciality (re)insurer on the CHF 500m hybrid bond. 700m. redomiciliation of its FINMA licensed reinsur- – Zug Estates (SIX-listed) and Migros Bank on – A UHNWI entrepreneur in a shareholders’ and ance company Canopius Reinsurance Ltd from their inaugural bonds. control dispute in excess of CHF 100m. Switzerland to Bermuda and, subsequently, its – DDM Holdings, a specialist acquirer of dis- – A contractor in a USD 90m international arbi- Swiss holding company Canopius Ltd to tressed asset portfolios in Central and Eastern tration over an infrastructure project in the Jersey. Europe with its registered seat in Switzerland Middle East. – NYSE-listed Celanese Corporation on the and listed on Nasdaq OMX First North, on its acquisition of Nouryon’s redispersible polymer public rights issue. powders business offered under the Elotex Insolvency & Restructuring – Auris Medical Holding AG (NASDAQ-listed) on brand, including all respective production its first Controlled Equity Offering (structured Recent experience includes: facilities across Europe and Asia, all products as an «at the market offering»). – Acting as Swiss Counsel for the crossholder under the Elotex portfolio, as well as all cus- – Equatex AG (first private equity owned securi- ad hoc group of noteholders (representing in tomer agreements, technology and commer- ties dealer subject to prudential supervision excess of 70 % of holders of Nyrstar’s EUR cial facilities globally. of FINMA) in regulatory matters and its sale to 340m 8.5% 2019 notes, EUR 500m 6.875% – NYSE-listed Fortive Corporation on the acqui- the Computershare group of companies. 2024 notes and EUR 115m 5% convertible 2022 sition of the Advanced Sterilization Products – Helvetica Property Investors in licensing and notes) in Nyrstar’s restructuring. business from Ethicon, Inc., a subsidiary of regulatory matters as well as the listing of the – Providing legal advice as Swiss counsel to Johnson & Johnson. HSC Fund on SIX Swiss Exchange. Apollo International